Poly(2-oxazoline)s as materials for biomedical applications

Journal of Materials Science: Materials in Medicine

Volumn 25, Issue 5, 2014, Pages 1211-1225

  De La Rosa, Victor R ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GENE THERAPY; MEDICAL APPLICATIONS; POLYMERIC IMPLANTS;

BIOMEDICAL APPLICATIONS; GLOBAL VISION; POLY(2-OXAZOLINE)S;

FUNCTIONAL POLYMERS;

AMPHOTERICIN B; BIOMATERIAL; BORTEZOMIB; CYCLOSPORIN A; DRUG CARRIER; ETOPOSIDE; EXCIPIENT; NANOCARRIER; OXAZOLINE DERIVATIVE; PACLITAXEL; POLY(2 METHYL 2 OXAZOLINE); POLY(2 OXAZOLINE); POLYMER; PROTEIN; UNCLASSIFIED DRUG; OXAZOLE DERIVATIVE; POLY(2-OXAZOLINE);

ARTICLE; BIOCOMPATIBILITY; BIOMEDICINE; BIOSENSOR; CANCER THERAPY; CELL ADHESION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GENE TARGETING; HUMAN; HYDROGEL; IMPLANT; MICELLE; NONHUMAN; PRIORITY JOURNAL; REGENERATIVE MEDICINE; ANIMAL; CHEMISTRY; DEVICES; PROSTHESES AND ORTHOSES; TISSUE ENGINEERING;

ANIMALS; BIOCOMPATIBLE MATERIALS; DRUG CARRIERS; HUMANS; OXAZOLES; PROSTHESES AND IMPLANTS; TISSUE ENGINEERING;

EID: 84899971230     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-013-5034-y     Document Type: Article

References (163)

1. Staudinger H. Nobel lecture: macromolecular chemistry. http://www.nobelprize.org (1953). Accessed 15 Sep 2012.
2. Ringsdorf HH. Hermann Staudinger and the future of polymer research jubilees-beloved occasions for cultural piety. Angew Chem Int Ed Engl. 2004;43(9):1064-76.
3. Ringsdorf HH. Structure and properties of pharmacologically active polymers. J polym sci C. 1975;51(1):135-53. doi:10.1002/polc.5070510111.
4. Haag R, Kratz F. Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl. 2006;45(8):1198-215. (Pubitemid 44097641)
5. Lendlein A, Pierce B, Ambrosio L, Grijpma. Special issue: advanced functional polymers for medicine. Macromol Biosci. 2011;11(12):1613-768.
6. Schlaad H, Hoogenboom R. Special issue: poly(2-oxazoline)s and related pseudo-polypeptides. Macromol Rapid Commun. 2012;33(19):1593-719.
7. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7(1):21-39.
8. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2(5):347-60. (Pubitemid 37361705)
9. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev. 2003;55(10):1261-77. (Pubitemid 37464561)
10. Jevševar S, Kunstelj M, Porekar VG. PEGylation of therapeutic proteins. Biotechnol J. 2010;5(1):113-28.
11. Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release. 2012;161(2):461-72.
12. Levy Y, Hershfield MS, Fernandez-Mejia C, Polmar SH, Scudiery D, Berger M, et al. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. J Pediatr. 1988;113(2):312-7.
13. Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007;110(1):103-11. (Pubitemid 46986423)
14. Tagami T, Nakamura K, Shimizu T, Yamazaki N, Ishida T, Kiwada H. CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes. J Control Release. 2010;142(2):160-6.
15. Zhao Y, Wang C, Wang L, Yang Q, Tang W, She Z, et al. A frustrating problem: accelerated blood clearance of PEGylated solid lipid nanoparticles following subcutaneous injection in rats. Eur J Pharm Biopharm. 2012;81(3):506-13.
16. Suzuki T, Ichihara M, Hyodo K, Yamamoto E, Ishida T, Kiwada H, et al. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs. Int J Pharm. 2012;436(1-2):636-43.
17. Ma Y, Yang Q, Wang L, Zhou X, Zhao Y, Deng Y. Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats. Eur J Pharm Sci. 2012;45(5):539-45.
18. Arima Y, Toda M, Iwata H. Complement activation on surfaces modified with ethylene glycol units. Biomaterials. 2008;29(5):551-60. (Pubitemid 350100805)
19. Moghimi SM, Hunter AC, Dadswell CM, Savay S, Alving CR, Szebeni J. Causative factors behind poloxamer 188 (Pluronic F68, Flocor™)-induced complement activation in human sera: a protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. Biochim Biophys Acta. 2004;1689(2):103-13. (Pubitemid 38766145)
20. Hamad I, Hunter AC, Szebeni J, Moghimi SM. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immunol. 2008;46(2):225-32.
21. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl. 2010;49(36):6288-308.
22. Barz M, Luxenhofer R, Zentel R, Vicent MJ. Overcoming the PEG-addiction: well-defined alternatives to PEG, from structure-property relationships to better defined therapeutics. Polym Chem. 2011;2(9):1900-18.
23. Veronese FM, editor. PEGylated protein drugs: basic science and clinical applications. Milestones in drug therapy. Basel: Springer; 2009.
24. Lee JS, Feijen J. Polymersomes for drug delivery: design, formation and characterization. J Control Release. 2012;161(2):473-83.
25. Fleige E, Quadir MA, Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv Drug Deliv Rev. 2012;64(9):866-84.
26. Duncan R, Vicent MJ. Polymer therapeutics-prospects for 21st century: the end of the beginning. Adv Drug Deliv Rev. 2012;65(1):60-70.
27. Tomalia DA, Sheetz DP. Homopolymerization of 2-alkyl- and 2-aryl-2-oxazolines. J Polym Sci A. 1966;4(9):2253-65.
28. Seeliger W, Aufderhaar E, Diepers W, Feinauer R, Nehring R, Thier W, et al. Recent syntheses and reactions of cyclic imidic esters. Angew Chem Int Ed Engl. 1966;5(10):875-88.
29. Kagiya T, Narisawa S, Maeda T, Fukui K. Ring-opening polymerization of 2-substituted 2-oxazolines. J Polym Sci C. 1966;4(7):441-5.
30. Bassiri TG, Levy A, Litt M. Polymerization of cyclic imino ethers. I. Oxazolines. J Polym Sci C. 1967;5(9):871-9.
31. Hoogenboom R. Poly(2-oxazoline)s: a polymer class with numerous potential applications. Angew Chem Int Ed Engl. 2009;48(43):7978-94.
32. Adams N, Schubert US. Poly(2-oxazolines) in biological and biomedical application contexts. Adv Drug Deliv Rev. 2007;59(15):1504-20. (Pubitemid 350122776)
33. Hoogenboom R, Schlaad H. Bioinspired poly(2-oxazoline)s. Polymers. 2011;3(1):467-88.
34. Schlaad H, Diehl C, Gress A, Meyer M, Demirel AL, Nur Y, et al. Poly(2-oxazoline)s as smart bioinspired polymers. Macromol Rapid Commun. 2010;31(6):511-25.
35. Sedlacek O, Monnery BD, Filippov SK, Hoogenboom R, Hruby M. Poly(2-oxazoline)s - are they more advantageous for biomedical applications than other polymers? Macromol Rapid Commun. 2012;33(19):1648-62.
36. Woodle MC, Engbers CM, Zalipsky S. New amphipatic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes. Bioconjug Chem. 1994;5(6):493-6.
37. Mero A, Pasut G, Via LD, Fijten MWM, Schubert US, Hoogenboom R, Veronese FM. Synthesis and characterization of poly(2-ethyl 2-oxazoline)-conjugates with proteins and drugs: suitable alternatives to PEG-conjugates? J Control Release. 2008;125(2):87-95.
38. Bauer M, Lautenschlaeger C, Kempe K, Tauhardt L, Schubert US, Fischer D. Poly(2-ethyl-2-oxazoline) as alternative for the stealth polymer poly(ethylene glycol): comparison of in vitro cytotoxicity and hemocompatibility. Macromol Biosci. 2012;12(7):986-98.
39. Viegas TX, Bentley MD, Harris JM, Fang Z, Yoon K, Dizman B, et al. Polyoxazoline: chemistry, properties, and applications in drug delivery. Bioconjug Chem. 2011;22(5):976-86.
40. Aoi K, Okada M. Polymerization of oxazolines. Prog Polym Sci. 1996;21(1):151-208. (Pubitemid 126403991)
41. Kobayashi S. Polymerization of oxazolines. In: Krzysztof M, Martin M, editors. Polymer science: a comprehensive reference. Amsterdam: Elsevier; 2012. p. 397-426.
42. Kobayashi S, Uyama H, Narita Y, Ishiyama J. Novel multifunctional initiators for polymerization of 2-oxazolines. Macromolecules. 1992;25(12):3232-6.
43. Paulus RM, Becer CR, Hoogenboom R, Schubert US. Acetyl halide initiator screening for the cationic ring-opening polymerization of 2-ethyl-2-oxazoline. Macromol Chem Phys. 2008;209(8):794-800.
44. Hoogenboom R, Fijten MWM, Kickelbick G, Schubert US. Synthesis and crystal structures of multifunctional tosylates as basis for star-shaped poly(2-ethyl-2-oxazoline)s. Beilstein J Org Chem. 2010;6:773-83.
45. Luxenhofer R, Bezen M, Jordan R. Kinetic investigations on the polymerization of 2-oxazolines using pluritriflate initators. Macromol Rapid Commun. 2008;29(18):1509-13.
46. Kowalczuk A, Kronek J, Bosowska K, Trzebicka B, Dworak A. Star poly(2-ethyl-2-oxazoline)s - synthesis and thermosensitivity. Polym Int. 2011;60(7):1001-9.
47. Tasdelen MA, Kahveci MU, Yagci Y. Telechelic polymers by living and controlled/living polymerization methods. Prog Polym Sci. 2011;36(4):455-567.
48. Glassner M, Kempe K, Schubert US, Hoogenboom R, Barner-Kowollik C. One-pot synthesis of cyclopentadienyl endcapped poly(2-ethyl-2-oxazoline) and subsequent ambient temperature Diels-Alder conjugations. Chem Commun. 2011;47(38):10620-2.
49. Volet G, Lav T-X, Babinot J, Amiel C. Click-chemistry: an alternative way to functionalize poly(2-methyl-2-oxazoline). Macromol Chem Phys. 2011;212(2):118-24.
50. Park J-S, Akiyama Y, Winnik FM, Kataoka K. Versatile synthesis of end-functionalized thermosensitive poly(2-isopropyl-2-oxazolines). Macromolecules. 2004;37(18):6786-92.
51. Hoogenboom R, Wiesbrock F, Leenen MAM, Thijs HML, Huang H, Fustin C-A, et al. Synthesis and aqueous micellization of amphiphilic tetrablock ter- and quarterpoly(2-oxazoline)s. Macromolecules. 2007;40(8):2837-43. (Pubitemid 46686435)
52. Fustin C-A, Thijs-Lambermont HML, Hoeppener S, Hoogenboom R, Schubert US, Gohy J-F. Multiple micellar morphologies from tri- and tetrablock copoly(2-oxazoline)s in binary water-ethanol mixtures. J Polym Sci A. 2010;48(14):3095-102.
53. Krumm C, Fik CP, Meuris M, Dropalla GJ, Geltenpoth H, Sickmann A, et al. Well-defined amphiphilic poly(2-oxazoline) ABA-triblock copolymers and their aggregation behavior in aqueous solution. Macromol Rapid Commun. 2012;33(19):1677-82.
54. Rossegger E, Schenk V, Wiesbrock F. Design strategies for functionalized poly(2-oxazoline)s and derived materials. Polymers. 2013;5(3):956-1011.
55. Hoogenboom R. Polyethers and polyoxazolines. In: Dubois P, Coulembier O, Raquez J-M, editors. Handbook of ring-opening polymerization. Weinheim: Wiley; 2009. p. 141-64.
56. Guillerm B, Monge S, Lapinte V, Robin J-J. How to modulate the chemical structure of polyoxazolines by appropriate functionalization. Macromol Rapid Commun. 2012;33(19):1600-12.
57. Salzinger S, Huber S, Jaksch S, Busch P, Jordan R, Papadakis C. Aggregation behavior of thermo-responsive poly(2-oxazoline)s at the cloud point investigated by FCS and SANS. Colloid Polym Sci. 2012;290(5):385-400.
58. Obeid R, Maltseva E, Thünemann AF, Tanaka F, Winnik FoM. Temperature response of self-assembled micelles of telechelic hydrophobically modified poly(2-alkyl-2-oxazoline)s in water. Macromolecules. 2009;42(6):2204-14.
59. Diehl C, Schlaad H. Thermo-responsive polyoxazolines with widely tuneable LCST. Macromol Biosci. 2009;9(2):157-61.
60. Huber S, Jordan R. Modulation of the lower critical solution temperature of 2-alkyl-2-oxazoline copolymers. Colloid Polym Sci. 2008;286(4):395-402.
61. Hoogenboom R, Thijs HML, Jochems MJHC, van Lankvelt BM, Fijten MWM, Schubert US. Tuning the LCST of poly(2-oxazoline)s by varying composition and molecular weight: alternatives to poly(N-isopropylacrylamide)? Chem Commun. 2008;44:5758-60.
62. Meyer M, Antonietti M, Schlaad H. Unexpected thermal characteristics of aqueous solutions of poly(2-isopropyl-2-oxazoline). Soft Matter. 2007;3(4):430-1. (Pubitemid 46449572)
63. Park J-S, Kataoka K. Comprehensive and accurate control of thermosensitivity of poly(2-alkyl-2-oxazoline)s via well-defined gradient or random copolymerization. Macromolecules. 2007;40(10):3599-609. (Pubitemid 46841916)
64. Park J-S, Kataoka K. Precise control of lower critical solution temperature of thermosensitive poly(2-isopropyl-2-oxazoline) via gradient copolymerization with 2-ethyl-2-oxazoline as a hydrophilic comonomer. Macromolecules. 2006;39(19):6622-30. (Pubitemid 44555107)
65. Diab C, Akiyama Y, Kataoka K, Winnik FM. Microcalorimetric study of the temperature-induced phase separation in aqueous solutions of poly(2-isopropyl-2-oxazolines). Macromolecules. 2004;37(7):2556-62.
66. Christova D, Velichkova R, Loos W, Goethals EJ, Prez FD. New thermo-responsive polymer materials based on poly(2-ethyl-2-oxazoline) segments. Polymer. 2003;44(8):2255-61. (Pubitemid 36362338)
67. Chen FP, Ames AE, Taylor LD. Aqueous solutions of poly(ethyloxazoline) and its lower consolute phase transition. Macromolecules. 1990;23(21):4688-95.
68. Bloksma MM, Weber C, Perevyazko IY, Kuse A, Baumgärtel A, Vollrath A, et al. Poly(2-cyclopropyl-2-oxazoline): from rate acceleration by cyclopropyl to thermoresponsive properties. Macromolecules. 2011;44(11):4057-64.
69. Luxenhofer R, Han Y, Schulz A, Tong J, He Z, Kabanov AV, et al. Poly(2-oxazoline)s as polymer therapeutics. Macromol Rapid Commun. 2012;33(19):1613-31.
70. Kempe K, Hoogenboom R, Jaeger M, Schubert US. Three-fold metal-free efficient ("Click") reactions onto a multifunctional poly(2-oxazoline) designer Scaffold. Macromolecules. 2011;44(16):6424-32.
71. Sosnik A, Gotelli G, Abraham GA. Microwave-assisted polymer synthesis (MAPS) as a tool in biomaterials science: how new and how powerful. Prog Polym Sci. 2011;36(8):1050-78.
72. Hoogenboom R, Schubert US. Microwave-assisted polymer synthesis: recent developments in a rapidly expanding field of research. Macromol Rapid Commun. 2007;28(4):368-86. (Pubitemid 47264266)
73. Bogdal D. Microwave-assisted polymerization. In: Krzysztof M, Martin M, editors. Polymer science: a comprehensive reference. Amsterdam: Elsevier; 2012. p. 981-1027.
74. Hoogenboom R, Fijten MWM, Paulus RM, Thijs HML, Hoeppener S, Kickelbick G, et al. Accelerated pressure synthesis and characterization of 2-oxazoline block copolymers. Polymer. 2006;47(1):75-84. (Pubitemid 41817458)
75. Wiesbrock F, Hoogenboom R, Leenen M, van Nispen SFGM, van der Loop M, Abeln CH, et al. Microwave-assisted synthesis of a 42-membered library of diblock copoly(2-oxazoline)s and chain-extended homo poly(2-oxazoline)s and their thermal characterization. Macromolecules. 2005;38(19):7957-66. (Pubitemid 41396677)
76. Hoogenboom R, Wiesbrock F, Leenen MAM, Meier MAR, Schubert US. Accelerating the living polymerization of 2-nonyl-2-oxazoline by implementing a microwave synthesizer into a high-thrxoughput experimentation workflow. J Comb Chem. 2004;7(1):10-3. (Pubitemid 40221560)
77. Kranenburg JM, Tweedie CA, Hoogenboom R, Wiesbrock F, Thijs HML, Hendriks CE, et al. Elastic moduli for a diblock copoly(2-oxazoline) library obtained by high-throughput screening. J Mater Chem. 2007;17(26):2713-21. (Pubitemid 47138962)
78. U.S. Department of Health and Human Services. Food and Drug Administration. M3(R2) Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. 2010. http://www.fda.gov/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ default.htm. Accessed 20 July 2013.
79. European Medicines Agency. ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. 2009. EMA/CPMP/ICH/286/1995.
80. SciFinder. Chemical abstracts service: Columbus. https://scifindercas.org (2012). Accessed 15 Sep 2012.
81. Luxenhofer R, Sahay G, Schulz A, Alakhova D, Bronich TK, Jordan R, et al. Structure-property relationship in cytotoxicity and cell uptake of poly(2-oxazoline) amphiphiles. J Control Release. 2011;153(1):73-82.
82. Wang X, Li X, Li Y, Zhou Y, Fan C, Li W, et al. Synthesis, characterization and biocompatibility of poly(2-ethyl-2-oxazoline)-poly(D,L- lactide)-poly(2-ethyl-2-oxazoline) hydrogels. Acta Biomater. 2011;7(12):4149-59.
83. Kronek J, Kroneková Z, Lustoň J, Paulovičová E, PaulovičováL, Mendrek B. In vitro bio-immunological and cytotoxicity studies of poly(2-oxazolines). J Mater Sci Mater Med. 2011;22(7):1725-34.
84. Konradi R, Acikgoz C, Textor M. Polyoxazolines for nonfouling surface coatings - a direct comparison to the gold standard PEG. Macromol Rapid Commun. 2012;33(19):1663-76.
85. Zalipsky S, Hansen CB, Oaks JM, Allen TM. Evaluation of blood clearance rates and biodistribution of poly(2-oxazoline)-grafted liposomes. J Pharm Sci. 1996;85(2):133-7.
86. Pidhatika B, Rodenstein M, Chen Y, Rakhmatullina E, Mühlebach A, Acikgöz C, et al. Comparative stability studies of poly(2-methyl-2- oxazoline) and poly(ethylene glycol) brush coatings. Biointerphases. 2012;7(1):1-15.
87. Goddard P, Hutchinson LE, Brown J, Brookman LJ. Soluble polymeric carriers for drug delivery. Part 2. Preparation and in vivo behaviour of N-acylethylenimine copolymers. J Control Release. 1989;10(1):5-16. (Pubitemid 19253809)
88. Gaertner FC, Luxenhofer R, Blechert B, Jordan R, Essler M. Synthesis, biodistribution and excretion of radiolabeled poly(2-alkyl-2-oxazoline)s. J Control Release. 2007;119(3):291-300. (Pubitemid 46770877)
89. Wang C-H, Hwang Y-S, Chiang P-R, Shen C-R, Hong W-H, Hsiue G-H. Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel. Biomacromolecules. 2011;13(1):40-8.
90. Duncan R. Polymer therapeutics as nanomedicines: new perspectives. Curr Opin Biotechnol. 2011;22(4):492-501.
91. Mero A, Fang Z, Pasut G, Veronese FM, Viegas TX. Selective conjugation of poly(2-ethyl 2-oxazoline) to granulocyte colony stimulating factor. J Control Release. 2012;159(3):353-61.
92. Tong J, Luxenhofer R, Yi X, Jordan R, Kabanov AV. Protein modification with amphiphilic block copoly(2-oxazoline)s as a new platform for enhanced cellular delivery. Mol Pharm. 2010;7(4):984-92.
93. European Medicines Agency. Summary of the European public assessment report (EPAR) for Glybera. 2012. http://www.ema.europa.eu. Accessed 20 July 2013.
94. Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 1999;286(5448):2244-5. (Pubitemid 30016842)
95. Boyce N. Trial halted after gene shows up in semen. Nature. 2001;414(6865):677. (Pubitemid 34000734)
96. Check E. Gene therapy: a tragic setback. Nature. 2002;420(6912):116-8.
97. Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit J-P. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials. 2008;29(24-25):3477-96.
98. O'Rorke S, Keeney M, Pandit A. Non-viral polyplexes: scaffold mediated delivery for gene therapy. Prog Polym Sci. 2010;35(4):441-58.
99. Wong SY, Pelet JM, Putnam D. Polymer systems for gene delivery - past, present, and future. Prog Polym Sci. 2007;32(8-9):799-837. (Pubitemid 47198291)
100. Gosselin MA, Guo W, Lee RJ. Efficient gene transfer using reversibly cross-linked low molecular weight polyethylenimine. Bioconjug Chem. 2001;12(6):989-94. (Pubitemid 33136869)
101. Breunig M, Lungwitz U, Liebl R, Fontanari C, Klar J, Kurtz A, et al. Gene delivery with low molecular weight linear polyethylenimines. J Gene Med. 2005;7(10):1287-98. (Pubitemid 41555435)
102. Brissault B, Kichler A, Guis C, Leborgne C, Danos O, Cheradame H. Synthesis of linear polyethylenimine derivatives for DNA transfection. Bioconjug Chem. 2003;14(3):581-7. (Pubitemid 36597368)
103. Lambermont-Thijs HML, van der Woerdt FS, Baumgaertel A, Bonami L, Du Prez FE, Schubert US, et al. Linear poly(ethylene imine)s by acidic hydrolysis of poly(2-oxazoline)s: kinetic screening, thermal properties, and temperature-induced solubility transitions. Macromolecules. 2009;43(2):927-33.
104. Thomas M, Lu JJ, Ge Q, Zhang C, Chen J, Klibanov AM. Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc Natl Acad Sci USA. 2005;102(16):5679-84. (Pubitemid 40559619)
105. Jeong JH, Song SH, Lim DW, Lee H, Park TG. DNA transfection using linear poly(ethylenimine) prepared by controlled acid hydrolysis of poly(2-ethyl-2-oxazoline). J Control Release. 2001;73(2-3):391-9. (Pubitemid 32539265)
106. Hsiue G-H, Chiang H-Z, Wang C-H, Juang T-M. Nonviral gene carriers based on diblock copolymers of poly(2-ethyl-2-oxazoline) and linear polyethylenimine. Bioconjug Chem. 2006;17(3):781-6. (Pubitemid 43794389)
107. Bauhuber S, Liebl R, Tomasetti L, Rachel R, Goepferich A, Breunig M. A library of strictly linear poly(ethylene glycol)-poly(ethylene imine) diblock copolymers to perform structure-function relationship of non-viral gene carriers. J Control Release. 2012;162(2):446-55.
108. von Erlach T, Zwicker S, Pidhatika B, Konradi R, Textor M, Hall H, et al. Formation and characterization of DNA-polymer-condensates based on poly(2-methyl-2-oxazoline) grafted poly(L-lysine) for non-viral delivery of therapeutic DNA. Biomaterials. 2011;32(22):5291-303.
109. Grayson SM, Cortez M, inventors; Polyplex Gene Delivery Vectors. International Patent WO 2011/116371. 2011.
110. Grayson SM. Polymer preprints (American Chemical Society, Division of Polymer Chemistry). 2012;53(1):370-1.
111. Canal F, Sanchis J, Vicent MJ. Polymer-drug conjugates as nano-sized medicines. Curr Opin Biotechnol. 2011;22(6):894-900.
112. Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev. 2009;61(13):1203-13.
113. Moreadith RW, Viegas TX, Standaert DG, Bentley MD, Fang Z, Dizman B, Yoon K, Weimer R, Harris JM, Ravenscroft P, Johnston TH, Hill M, Brotchie JM. SER-214, a novel polymer-conjugated rotigotine formulation affords greatly extended duration of anti-Parkinsonian effect and enhanced plasma exposure following a single administration in rodents and primates. Proceedings of the 16th international conference of Parkinson's disease and movement disorders, movement disorder society; Jun 17-21, 20125; Dublin, Ireland. Late breaking abstract 5, 2012.
114. Serina Therapeutics. US Patent and Trademark Office awards Serina Therapeutics key patent covering its lead clinical candidate for Parkinson's disease and restless leg syndrome. 2013. http://www.serinatherapeutics.com/. Accessed 20 July 2013.
115. Wei H, Zhuo R-X, Zhang X-Z. Design and development of polymeric micelles with cleavable links for intracellular drug delivery. Prog Polym Sci. 2012;38(3-4):103-35.
116. Tyrrell ZL, Shen Y, Radosz M. Fabrication of micellar nanoparticles for drug delivery through the self-assembly of block copolymers. Prog Polym Sci. 2010;35(9):1128-43.
117. Chacko RT, Ventura J, Zhuang J, Thayumanavan S. Polymer nanogels: a versatile nanoscopic drug delivery platform. Adv Drug Deliv Rev. 2012;64(9):836-51.
118. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 2009;100(4):572-9.
119. Onaca O, Enea R, Hughes DW, Meier W. Stimuli-responsive polymersomes as nanocarriers for drug and gene delivery. Macromol Biosci. 2009;9(2):129-39.
120. Nardin C, Thoeni S, Widmer J, Winterhalter M, Meier W. Nanoreactors based on (polymerized) ABA-triblock copolymer vesicles. Chem Commun. 2000;15:1433-4. (Pubitemid 30621943)
121. Ben-Haim N, Broz P, Marsch S, Meier W, Hunziker P. Cell-specific integration of artificial organelles based on functionalized polymer vesicles. Nano Lett. 2008;8(5):1368-73.
122. Broz P, Ben-Haim N, Grzelakowski M, Marsch S, Meier W, Hunziker P. Inhibition of macrophage phagocytotic activity by a receptor-targeted polymer vesicle-based drug delivery formulation of pravastatin. J Cardiovasc Pharmacol. 2008;51(3):246-52. (Pubitemid 351450602)
123. Ranquin A, Versées W, Meier W, Steyaert J, Van Gelder P. Therapeutic nanoreactors: combining chemistry and biology in a novel triblock copolymer drug delivery system. Nano Lett. 2005;5(11):2220-4. (Pubitemid 41698942)
124. Trzebicka B, Koseva N, Mitova V, Dworak A. Organization of poly(2-ethyl-2-oxazoline)-block-poly(2-phenyl-2-oxazoline) copolymers in water solution. Polymer. 2010;51(12):2486-93.
125. Milonaki Y, Kaditi E, Pispas S, Demetzos C. Amphiphilic gradient copolymers of 2-methyl- and 2-phenyl-2-oxazoline: self-organization in aqueous media and drug encapsulation. J Polym Sci A. 2012;50(6):1226-37.
126. Krumm C, Fik CP, Meuris M, Dropalla GJ, Geltenpoth H, Sickmann A, et al. Well-defined amphiphilic poly(2-oxazoline) ABA-triblock copolymers and their aggregation behavior in aqueous solution. Macromol Rapid Commun. 2012;33(19):1677-82.
127. Persidis A. Cancer multidrug resistance. Nat Biotechnol. 1999;17(1):94-5. (Pubitemid 29037219)
128. Luxenhofer R, Schulz A, Roques C, Li S, Bronich TK, Batrakova EV, et al. Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs. Biomaterials. 2010;31(18):4972-9.
129. Han Y, He Z, Schulz A, Bronich TK, Jordan R, Luxenhofer R, et al. Synergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micelles. Mol Pharm. 2012;9(8):2302-13.
130. Lutolf MP. Biomaterials: spotlight on hydrogels. Nat Mater. 2009;8(6):451-3.
131. Kelly AM, Hecke A, Wirnsberger B, Wiesbrock F. Synthesis of poly(2-oxazoline)-based hydrogels with tailor-made swelling degrees capable of stimuli-triggered compound release. Macromol Rapid Commun. 2011;32(22):1815-9.
132. Dargaville TR, Forster R, Farrugia BL, Kempe K, Voorhaar L, Schubert US, et al. Poly(2-oxazoline) hydrogel monoliths via thiol-ene coupling. Macromol Rapid Commun. 2012;33(19):1695-700.
133. http://www.gatt-tech.com/. Accessed 20 Oct 2012.
134. Hoogenboom R, Bender J, Van Hest J, inventors; Cross-linked polymers and implants derived from electrophilically activated polyoxazoline. International Patent WO 2012/057628. 2012.
135. Kelly AM, Wiesbrock F. Strategies for the synthesis of poly (2-oxazoline)-based hydrogels. Macromol Rapid Commun. 2012;33(19):1632-47.
136. Del Pozo JL, Patel R. Infection associated with prosthetic joints. N Engl J Med. 2009;361(8):787-94.
137. Werner C, Maitz MF, Sperling C. Current strategies towards hemocompatible coatings. J Mater Chem. 2007;17(32):3376-84. (Pubitemid 47231013)
138. Krishnan S, Weinman CJ, Ober CK. Advances in polymers for anti-biofouling surfaces. J Mater Chem. 2008;18(29):3405-13.
139. Vogler EA. Structure and reactivity of water at biomaterial surfaces. Adv Colloid Interface Sci. 1998;74(1-3):69-117. (Pubitemid 128424313)
140. Vogler EA. In: Morra M, editor. Water in biomaterials surface science. 1st ed. New York: Wiley; 2001.
141. Roosjen A, de Vries J, van der Mei HC, Norde W, Busscher HJ. Stability and effectiveness against bacterial adhesion of poly(ethylene oxide) coatings in biological fluids. J Biomed Mater B. 2005;73B(2):347-54. (Pubitemid 40628998)
142. Bozzini S, Petrini P, Tanzi MC, Zürcher S, Tosatti S. Poly(ethylene glycol) and hydroxy functionalized alkane phosphate mixed self-assembled monolayers to control nonspecific adsorption of proteins on titanium oxide surfaces. Langmuir. 2009;26(9):6529-34.
143. Van Kuringen HPC, Lenoir J, Adriaens E, Bender J, De Geest BG, Hoogenboom R. Partial hydrolysis of poly(2-ethyl-2-oxazoline) and potential implications for biomedical applications? Macromol Biosci. 2012;12(8):1114-23.
144. Konradi R, Pidhatika B, Muhlebach A, Textor M. Poly-2-methyl-2-oxazoline: a peptide-like polymer for protein-repellent surfaces. Langmuir. 2008;24(3):613-6. (Pubitemid 351270917)
145. Pidhatika B, ller J, Vogel V, Konradi R. Nonfouling surface coatings based on poly(2-methyl-2-oxazoline). CHIMIA Int J Chem. 2008;62(4):264-9.
146. Pidhatika B, Möller J, Benetti EM, Konradi R, Rakhmatullina E, Mühlebach A, et al. The role of the interplay between polymer architecture and bacterial surface properties on the microbial adhesion to polyoxazoline-based ultrathin films. Biomaterials. 2010;31(36):9462-72.
147. Chang B-J, Prucker O, Groh E, Wallrath A, Dahm M, Rühe J. Surface-attached polymer monolayers for the control of endothelial cell adhesion. Colloid Surf A. 2002;198-200:519-26. (Pubitemid 34195379)
148. Murata H, Chang BJ, Prucker O, Dahm M, Rühe J. Polymeric coatings for biomedical devices. Surf Sci. 2004;570(1-2):111-8.
149. Wang H, Li L, Tong Q, Yan M. Evaluation of photochemically immobilized poly(2-ethyl-2-oxazoline) thin films as protein-resistant surfaces. ACS Appl Mater Interfaces. 2011;3(9):3463-71.
150. Jordan R, Ulman A. Surface initiated living cationic polymerization of 2-oxazolines. J Am Chem Soc. 1998;120(2):243-7. (Pubitemid 28062505)
151. Zhang N, Steenackers M, Luxenhofer R, Jordan R. Bottle-brush brushes: cylindrical molecular brushes of poly(2-oxazoline) on glassy carbon. Macromolecules. 2009;42(14):5345-51.
152. Zhang N, Pompe T, Amin I, Luxenhofer R, Werner C, Jordan R. Tailored poly(2-oxazoline) polymer brushes to control protein adsorption and cell adhesion. Macromol Biosci. 2012;12(7):926-36.
153. Zhang N, Luxenhofer R, Jordan R. Thermoresponsive poly(2-oxazoline) molecular brushes by living ionic polymerization: kinetic investigations of pendant chain grafting and cloud point modulation by backbone and side chain length variation. Macromol Chem Phys. 2012;213(9):973-81.
154. Charnley M, Textor M, Acikgoz C. Designed polymer structures with antifouling-antimicrobial properties. React Funct Polym. 2011;71(3):329-34.
155. Siedenbiedel F, Tiller JC. Antimicrobial polymers in solution and on surfaces: overview and functional principles. Polymers. 2012;4(1):46-71.
156. Fik CP, Krumm C, Muennig C, Baur TI, Salz U, Bock T, et al. Impact of functional satellite groups on the antimicrobial activity and hemocompatibility of telechelic poly(2-methyloxazoline)s. Biomacromolecules. 2011;13(1):165-72.
157. Waschinski CJ, Herdes V, Schueler F, Tiller JC. Influence of satellite groups on telechelic antimicrobial functions of polyoxazolines. Macromol Biosci. 2005;5(2):149-56. (Pubitemid 40803840)
158. Waschinski CJ, Zimmermann J, Salz U, Hutzler R, Sadowski G, Tiller JC. Design of contact-active antimicrobial acrylate-based materials using biocidal macromers. Adv Mater. 2008;20(1):104-8. (Pubitemid 351143302)
159. Bieser AM, Thomann Y, Tiller JC. Contact-active antimicrobial and potentially self-polishing coatings based on cellulose. Macromol Biosci. 2011;11(1):111-21.
160. Phadtare S, Vinod VP, Mukhopadhyay K, Kumar A, Rao M, Chaudhari RV, et al. Immobilization and biocatalytic activity of fungal protease on gold nanoparticle-loaded zeolite microspheres. Biotechnol Bioeng. 2004;85(6):629-37. (Pubitemid 38270495)
161. Tokarev I, Tokareva I, Gopishetty V, Katz E, Minko S. Specific biochemical-to-optical signal transduction by responsive thin hydrogel films loaded with noble metal nanoparticles. Adv Mater. 2010;22(12):1412-6.
162. Agrawal M, Rueda JC, Uhlmann P, Müller M, Simon F, Stamm M. Facile approach to grafting of poly(2-oxazoline) brushes on macroscopic surfaces and applications thereof. ACS Appl Mater Interfaces. 2012;4(3):1357-64.
163. Claeys B, Vervaeck A, Vervaet C, Remon JP, Hoogenboom R, De Geest BG. Poly(2-ethyl-2-oxazoline) as matrix excipient for drug formulation by hot melt extrusion and injection molding. Macromol Rapid Commun. 2012;33(19):1701-7.